BioXplor was tasked with identifying novel indications for an IL17A inhibitor, Cosentyx, for Novartis. The objective was to identify and prioritize novel indications for further clinical studies in inflammatory diseases, and to incorporate potential signals to explain adverse events. BioXplor analysed the pathogenic pathway of the disease and compared the treatment strategy with competing drug-target pathways in inflammation pathways. BioXplor's team utilized it's biomedical and drug disocvery knowledebase consisting of 250 databases and billions of structured biomedical literature sentences using natural language processing and machine learning models, to prioritize several novel indications based on safety and efficacy.
Case Study - Indication Expansion for Cosentyx
Indication Expansion, Adverse Events, Mechanisms
request more information
BioXplor set out to elucidate a novel pathogenic pathway for a rare disease called Lipedema, which is an inflammatory fat disorder, with very little published research. The team elucidated the pathway based on an initial gene found to be strongly associated with a rare genetic disease, and built out the pathway using indirect literature evidence supporting the genetic and clinical features that are known. The team proposed a novel therapeutic hypothesis with evidence to support drug repositioning. The identified target was then found to be highly-expressed in Lipedema patient tissues, and a leading Lipedema expert, an endocrinologist at University of Arizona, confirmed that the proposed candidate for drug repositioning was effective and safe for treatment of Lipedema patients, and was already being prescribed, even though this finding is not to be found in the biomedical literature. This is one of many examples of novel insights discovered using BioXplor's for novel pathway elucidation and drug target identification.
Case Study - Lipedema Drug Repositioning
Novel Pathway Elucidation, Drug Targets, Mechanisms of Action
Request more information
BioXplor's network immunopharmacology platform is being utilized to identify immunomodulation drug targets and drug combinations for COVID-19. The goal is to bring currently novel drug combinations to IND filing and subsequent clinical trials novel drug combinations with strong evidence of synergy, safety and efficacy for treatment of high-risk patients with severe disease in COVID-19.
Request More Information
Case Study - COVID-19 Drug Combinations